News
GED Capital successfully exits healthcare company Vitro Group through a dual-track process
GED Capital (“GED”) divested Vitro Group (“Vitro” or the “Company”) through a dual exit route, first selling its flow cytometry division…
Vitro S.A. sells Cytognos to BD to prioritize the market launch of their new and disruptive Molecular Biology and Anatomic Pathology diagnostic platforms.
Seville, Spain (January 31, 2022) –Vitro S.A, (www.vitro.bio) a privately held company headquartered in Seville, Spain, announced today the sale of Cytognos to Becton Dickinson and Company (BD). Cytognos is a company specializing…